



SCREENING LIMITS FOR THERAPEUTIC SUBSTANCES

For the purposes of AHHR Rule 188B, it is hereby notified that screening limits applicable to the following therapeutic substances, as approved by Harness Racing Australia, are set out as follows:

- Acepromazine – 0.02 nanograms per millilitre (ng/mL) in plasma
- Acepromazine – 10ng/mL of the 2-(1-hydroxyethyl) promazine sulphoxide metabolite in urine
- Betamethasone – 0.20ng/mL in urine
- Butorphanol – 0.01ng/mL in plasma
- Butorphanol – 1ng/mL in urine
- Carprofen – 100ng/mL in plasma
- Carprofen – 100ng/mL in urine
- Clenbuterol – 0.1ng/mL in urine (date of effect 1 April 2023)
- Dantrolene – 3ng/mL of the 5-hydroxydantrolene metabolite in unhydrolysed urine
- Detomidine – 0.02ng/mL of the 3'-hydroxydetomidine metabolite in plasma
- Detomidine - 2ng/mL of the 3'-hydroxydetomidine metabolite in urine
- Dexamethasone – 0.2ng/mL in plasma
- Dexamethasone – 0.2ng/mL in urine
- Diclofenac – 50ng/mL in urine
- Dipyrone – 1000ng/mL of the 4-methylaminoantipyrine metabolite in urine
- Eltenac – 50ng/mL in urine
- Firocoxib – 2ng/mL in plasma
- Flunixin -1ng/mL in plasma
- Flunixin – 100ng/mL in urine
- Frusemide – 0.1ng/mL in plasma
- Frusemide – 50ng/mL in urine
- Hyoscine butylbromide (or n-butylscopolammonium) – 0.05ng/mL in plasma
- Hyoscine butylbromide (or n-butylscopolammonium) – 25 ng/mL in urine
- Ipratropium – 0.25ng/mL in urine
- Ketoprofen – 2ng/mL in plasma under the condition of a single IV or oral dose
- Ketoprofen – 100ng/mL in urine
- Lignocaine – 0.05ng/mL in plasma
- Lignocaine – 10-ng/mL of the 3'-hydroxylignocaine metabolite in urine
- Meclofenamic acid – 5ng/mL in plasma
- Meclofenamic acid – 250ng/mL in urine
- Medetomidine - 0.02ng/mL of 3'-hydroxymedetomidine in plasma

- Medetomidine – 5ng/mL of 3'-hydroxymedetomidine in urine
- Meloxicam – 1ng/mL in plasma
- Meloxicam – 10ng/mL in urine
- Mepivacaine – 0.05ng/mL in plasma
- Mepivacaine – 10ng/mL of the 3'-hydroxymepivacaine metabolite in urine
- Methocarbamol – 100ng/mL in urine (when restricted to a single oral or IV treatment of no more than 5 grams of methocarbamol)
- Naproxen – 250ng/mL in urine
- Phenylbutazone – 100ng/mL in plasma
- Phenylbutazone – 100ng/mL in urine
- Procaine - 0.02ng/mL in plasma
- Procaine - 20ng/mL in urine
- Romifidine – 1ng/mL in urine
- Salbutamol – 0.5ng/mL in urine
- Triamcinolone acetonide – 0.5ng/mL in urine
- Vedaprofen – 5ng/mL in plasma
- Vedaprofen – 50ng/mL in urine

Date of Effect: 14 December 2018

Last updated: 22 February 2024